In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...
Computational tool improves recombinant virus design efficiency and yield.This innovative in-house development is a key component of Transgene’s ...
Vaccine manufacturing is challenged by stringent global regulations, essential for ensuring safety and efficacy, with ...
The causative agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first detected in Wuhan, China, in December 2019. To date, the virus ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
A Lassa fever vaccine candidate was safe and produced a strong immune response in adults in the United States and Liberia, ...
The recombinant vector vaccines segment accounted for a market share of more than 11% in the global veterinary market in 2016. Recombinant vector vaccines mimic a natural process of infection, but ...
CreoSG announced on the 13th that it has finalized the registration of a domestic patent for a Zika virus vaccine using the recombinant VSV (Vesicular Stomatitis Virus) vector system, a core ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback